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AbstrAct
Introduction Ventilation parameter data from patients 
receiving home mechanical ventilation can be collected 
via secure data cards and modem technology. This can 
then be reviewed by clinicians and ventilator prescriptions 
adjusted. Typically available measures include tidal 
volume (VT), leak, respiratory rate, minute ventilation, 
patient triggered breaths, achieved pressures and patient 
compliance. This study aimed to assess the potential 
impact of ventilator data downloads on management of 
patients requiring home non-invasive ventilation (NIV).
Methods A longitudinal within-group design with repeated 
measurements was used. Baseline ventilator data were 
downloaded, reviewed and adjustments made to optimise 
ventilation. Leak, VT and compliance data were collected 
for comparison at the first review and 3–7 weeks later. 
Ventilator data were monitored and amended remotely via 
a modem by a consultant physiotherapist between the first 
review and second appointment.
results Analysis of data from 52 patients showed 
increased patient compliance (% days used >4 hours) from 
90% to 96% (p=0.007), increased usage from 6.53 to 
6.94 hours (p=0.211) and a change in VT(9.4 vs 8.7 mL/kg/
ideal body weight, p=0.022). There was no change in leak 
following review of NIV prescriptions (mean (SD): 43 (23.4) 
L/min vs 45 (19.9)L/min, p=0.272).
conclusion Ventilator data downloads, via early remote 
assessment, can help optimise patient ventilation through 
identification of modifiable factors, in particular interface 
leak and ventilator prescriptions. However, a prospective 
study is required to assess whether using ventilator data 
downloads provides value in terms of patient outcomes 
and cost-effectiveness. The presented data will help to 
inform the design of such a study.
IntroductIon
Domiciliary non-invasive ventilation (NIV) is 
accepted as standard care for patients with 
chronic hypercapnic ventilatory failure.1 2 
The efficacy of domiciliary NIV is dependent 
on optimal ventilator support and the correct 
interface to optimise ventilation and mini-
mise side effects.3–5 
In keeping with healthcare policies of 
providing high quality and cost-effective care 
in the community,6 both numbers of people 
receiving and services delivering domiciliary 
NIV are increasing.7–9 Traditionally, people 
undergo an inpatient admission for initi-
ation of domiciliary NIV. With changing 
service models, more people are now being 
commenced on domiciliary NIV systems 
in outpatient or community settings. This 
has been shown to be as clinically effective 
as inpatient set-up in the neuromuscular 
disease (NMD) population10; cost effective-
ness within the obese population is currently 
being assessed.11 Improved patient expe-
rience, alongside reduced costs are other 
proposed benefits of outpatient initialisation 
of domiciliary NIV.11 Nevertheless, a concern 
remains that domiciliary NIV outpatient 
set-up reduces the capacity for monitoring 
and assessing patients in comparison with 
bedside monitoring and the use of traditional 
tools such as transcutaneous CO2 monitoring 
and arterial blood gases (ABGs).10 Janssens 
et al12 argue that ventilator data downloaded 
into specific software can be used as an alter-
native to support clinical decision-making in 
the successful management of domiciliary 
NIV. The use of ventilator data downloads 
Key messages
 ► Ventilator data downloads facilitate optimisation of 
delivery of domiciliary NIV.
 ► Ventilator data downloads can facilitate early, 
objective assessment of ventilator prescriptions 
and leak.
 ► Ventilator data downloads can facilitate outpatient 
setups and are a useful interventional adjunct in the 
clinicians’ toolbox.
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may therefore help promote the wider use of outpatient 
set-up for home NIV; indeed ventilator download data, 
transmitted via a modem, can be described as a form of 
telemedicine.13
Data are available by both Secure Data (SD) card down-
load and via modem technology, which means this data 
can be viewed remotely on a daily basis. Bench studies 
have demonstrated ventilator data parameters provided 
in manufacturers’ software are reliable14 15 and clinical 
studies have demonstrated the apnoea hypnoea index 
recorded by built in software is also reliable.16 Most 
recently, Borel et al17 demonstrated that ventilator down-
load data, particularly respiratory rate, trigger % and 
usage, can predict an exacerbation of chronic obstructive 
pulmonary disease (COPD).
To date, there is minimal evidence for using data 
downloads in the assessment, treatment and manage-
ment of people receiving domiciliary NIV.12 17–19 The 
European Respiratory Society task force has called for 
further research in the area.13 Therefore, this study 
aimed to assess the impact of using ventilator data 
downloads in the management of people with chronic 
hypercapnic ventilatory failure receiving domiciliary 
NIV.
Specifically, this study assessed the impact of ventilator 
data downloads on:
 ► Tidal volumes (VT);
 ► The incidence of large leaks and interface issues;
 ► Individual compliance with domiciliary NIV;
 ► The incidence of continued hypercapnia (partial 
pressure of carbon dioxide (PaCO2 >6 kPa).
Methods
ethics
After discussion with the research and development 
department, it was deemed that ethical approval was 
not required for this study as all data were anonymous 
and collected as part of routine practice. Participants 
completed a data protection consent form for the instal-
lation of a modem. The study was registered with the 
trust’s audit and governance department.
study design and participants
A longitudinal within-group repeated measures study 
design was used. All adult patients with chronic hyper-
capnic ventilatory failure receiving care under a domi-
ciliary NIV service at the Royal Free London National 
Health Service (NHS) Foundation Trust were eligible 
for study inclusion. All patients were offered a review 
appointment between December 2014 and April 2015 
and followed up by June 2015. Participants were excluded 
when they died during the study period, had their care 
transferred to another provider or declined to attend a 
review appointment.
Procedure
Prior to the review appointment, all patients had been 
managed with clinical assessment, including symptoms 
and PaCO2 measurements obtained via Capillary Blood 
Gas (CBG); data from the patients’ ventilators had not 
been used as part of their clinical management. The 
purpose of the review appointment was to:
 ► Exchange the participants’ current home ventilator 
for a new model which was fitted with a modem.
 ► Use the ventilator data downloads to ensure opti-
mal ventilation had been achieved, aiming for VT of 
8–10 mL/kg of ideal body weight.
 ► Review participants’ interface via the leak measure-
ment on the ventilator data download to ensure mini-
misation of both leak and side effects. Interfaces were 
changed or resized where participants had a leak 
of >60 L/min (as per manufacturer’s guidance).
 ► Ensure participants and carers had received verbal 
and written patient information leaflets regarding 
their condition, use, care of and maintenance of their 
ventilator, interface and accessories.
Participants with VT <6 mL/kg of ideal body 
weight or >10 mL/kg of ideal body weight were opti-
mised through the use of a Philips Respironics A40 
ventilator (Philips Respironics, Murraysville, USA) 
utilising Average Volume Assured Pressure Support/
Average Volume Assured Pressure Support-Auto Expira-
tory Positive Airway Pressure (AVAPS/AVAPS-AE) mode 
and employing a titration approach.11 In this study, the 
titration approach involved using AVAPS-AE mode over 
4–6 weeks to evaluate the NIV prescription required by 
each participant.
All participants were monitored via the modem tech-
nology and EncoreAnywhere (Philips Respironics) 
system to measure and ensure:
 ► optimal ventilation, aiming for 8–10 mL/kg of ideal 
body weight;
 ► minimal leak;
 ► minimal side effects;
 ► optimal compliance, aiming for >4 hours/night for 
70% of nights.
Data from the modems were reviewed by a consultant 
physiotherapist routinely twice weekly and when 
patients contacted the service. Participants were 
invited to a follow-up appointment on average 6 weeks 
post initial review appointment depending on appoint-
ment and patient availability. The purpose of this visit 
was to:
 ► Provide an appropriate ventilator for participants 
who required retitration: Philips Respironics A40, 
A30 or BiPAP ST (Philips Respironics).
 ► Ensure optimal ventilation had been achieved: aim-
ing for VT of 8–10 mL/kg of ideal body weight.
 ► Ensure interface was optimised to minimise both leak 
and side effects. 
 ► Review patient compliance. 
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outcome measures
Ventilator data and PaCO2 were collected by clinicians 
with appropriate skills and knowledge in domiciliary NIV 
but who had not provided care for the study participants.
NIV data
Data were collected at the initial review appointment to 
act as the historical control for the cohort and further 
at the follow-up appointment 3–7 weeks later. Venti-
lator parameter data were collected via SD cards and 
subsequently modems to measure the following study 
outcomes: ventilator prescription, leak, VT (average over 
last 7 days of the data collection period) and compliance 
assessed as percentage of days NIV used >4 hours in the 
previous 28 days and average hours/day of NIV on days 
NIV was used.
Capillary blood gas
PaCO2 were obtained by trained clinicians via CBGs. CBGs 
were analysed on a RAPIDPoint 500 blood gas system 
(Siemens, UK). Where CBGs had been undertaken as 
part of the participant’s normal care within 1 month, and 
there had been no clinical change in the participant’s 
status, CBG data were collected from clinic letters.
data analysis
Data were analysed using SPSS V.22 by an independent 
statistician. Descriptive statistics were used to report 
the demographics of the cohort. Data were analysed 
as paired data using a t-test. VT, respiratory rate, Ti 
and PaCO2 levels were analysed using the paired t-test. 
Compliance, leak and ventilator prescription data were 
analysed with the Wilcoxon rank sum. The McNemar test 
was used to determine if there were differences in hyper-
capnic respiratory failure (defined as PaCO2 >6 kPa). To 
assess if persistent hypercapnia was associated with leak, 
compliance or VT, an analysis of variance between partici-
pants who remained hypercapnic and participants where 
hypercapnia had resolved after review was undertaken.
results
Participants
At the start of the study, there were 78 participants. Data 
for 52 participants were analysed; data for the remaining 
Figure 1 Flow diagram of patient progress through the study. ITU, intensive treatment unit; NIV, non-invasive ventilation. 
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15 were not available (see figure 1). Patients were 
excluded if they declined to attend a review appoint-
ment, as ventilator data for comparison were not avail-
able for these patients. Where patients were excluded 
due to mortality, they had not attended a review appoint-
ment nor were issued with a replacement ventilator.
There were more females in the group (men:women, 
21:31) and the mean (SD) age of participants was 62 
(18.8) years. The main reason for NIV use was obesity-re-
lated respiratory failure (33%), followed by COPD (27%), 
multiple diagnoses (13%), NMD (12%), chest wall defor-
mity (10%) and other (6%). The median duration partic-
ipants had been receiving domiciliary NIV prior to their 
review appointment was 33 months (IQR 15–48 months). 
The median time between the participants’ review 
appointment and their last appointment in a respiratory 
clinic was 5.5 (IQR 1.6–9.7) months. At the first review 
appointment, the mean nightly use of NIV was 6.53 hours 
and mean compliance was 90%, where compliance was 
defined as >4 hours/night NIV use for >70% of nights.20 
Prior to review, most participants used nasal (63%) and 
full face (27%) interfaces; post-review this was 56% and 
31%, respectively (table 1).
Seventy-nine per cent (n=41) of patients required a 
change in their interface prescription, either in mask 
type or size. Eighty-seven per cent (n=45) of participants 
required an amendment to their ventilator prescription 
(table 2).
Prior to changing their prescription, seven individuals 
were achieving a VT <6 mL/kg/ideal body weight and 
thus required an increase in the target VT. Twenty-three 
individuals, although having a VT >10 mL/kg/ideal body 
weight were thought to have been overventilated, and 
thus required titration of their ventilator prescription. 
Mean PaCO2 at the start of the study was 6.59 (1.04) and 
post intervention was 6.45 (0.72) (mean difference 0.13, 
95% CI -0.24 to 0.51, p=0.473).
VT and minute ventilation
VT measurements were available for 49 participants; the 
remaining participants were non-compliant and thus VT 
measurements were not available. Results demonstrated 
a significant change in both actual VT (mL) (mean differ-
ence 79.7 mL; 95% CI 12.1 to 147.2, p=0.022) and ideal 
VT (mL/kg/ideal body weight) (mean difference 1.23; 
95% CI 0.21 to 2.25, p=0.01) after prescription review 
(figure 2). There were two outliers whose VT had been 
kept intentionally higher than usually expected for 
clinical reasons. When a reduction in VT was trialled in 
these patients, they deteriorated and therefore their 
original prescription of >10 mL/kg ideal body weight 
was maintained. Following exclusion of the outliers, 
Table 1 Type of ventilator before and after review 
appointment
Ventilator (Philips 
Respironics) Before, % (n) After, % (n)
A30 6% (3) 10% (5)
A40 – 33% (17)
BiPAP ST 30 19% (10) 58% (30)
Harmony 67% (35) – 
Synchrony 8% (4) – 
Interface
  Divers 2% (1) 8% (4)
  Full face 27% (14) 31% (16)
  Nasal 63% (33) 56% (29)
  Pillows 8% (4) 6% (3)
Table 2 Domiciliary non-invasive ventilation prescription pre-review and post-review
Prescription
Before, % (n) or median 
(IQR)
After, %(n) or median 
(IQR) p value
Mode ST 98% (51) 71% (37) 0.791
S 2 % (1)   – 
AVAPS   – 8 % (4) 
AVAPS-AE   – 21 % (11) 
IPAP, cm H2O for the whole data set 20 (15–24) 20 (18–24) 0.005
IPAP, cm H2O (Clinician set) n=35 20 (16–21)
IPAP, cm H2O (AVAPS) n=18 24.5 (21.1–29.2)
EPAP, cm H2O 4 (4–6) 6 (4–6) <0.001
Pressure support, cm H2O 15 (10–18) 15.57 (12–18) 0.406
BPM 11 (11–18) 12 (12–12) <0.001
Ti (s) 1.4 (1–1.5) 1.5 (1.5–1.8) <0.001
Rise (100 ms) 1 (1–2) 3 (2–4) <0.001
Data are presented as median (IQR) unless otherwise stated.
AVAPS, Average Volume Assured Pressure Support; BPM, breaths per minute; cm H2O, centimetres of water; EPAP, Expiratory Positive 
Airway Pressure; IPAP, Iinspiratory Positive Airway Pressure; Ti, inspiratory time.
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there remained a statistically significant change in both 
VT (mL) (mean difference 91.1; 95% CI 27.4 to 154.8, 
p=0.006) and ideal VT (mean difference 1.38; 95% CI 
0.42 to 2.34, p=0.006). As demonstrated in figure 2, there 
was a reduction in the range of the VT. Where patients 
had a VT of >10 mL/kg/ideal body weight, there was a 
trend towards a reduction in their VT (mean pre-review: 
13.4 mL/kg/ideal body weight vs mean post-review: 
9.7 mL/kg/ideal body weight). Where patients had a VT 
of <6 mL/kg/ideal body weight, there was a trend towards 
an increase in their VT (mean pre-review 4.3 mL/kg/
ideal body weight vs mean post-review 6.5 mL/kg/ideal 
body weight). At the initial review appointment, 15% 
of patients had a VT of 8–10 mL/kg/ideal body weight 
versus 29% at the 6-week follow-up.
Minute ventilation measurements were available for 49 
participants; the remaining participants were non-com-
pliant and so minute volume measurements were not 
available. Results demonstrated an increase in minute 
ventilation after prescription review (mean difference 
0.11 L/min; 95% CI −0.69 to 0.92, p=0.781).
Leak
Leak measurements were available for 49 participants, 
where participants were non-compliant, leak measure-
ments were not available. There was no change in leak 
following review of NIV prescriptions (mean (SD): 43 
(23.4) L/min vs 45 (19.9) L/min, P=0.272). Manufactur-
er’s guidelines state that the ventilators used in this study 
are able to compensate for a leak of up to 60 L/min. 
Pre-review 12% (n=6) of participants had a measured 
leak >60 L/min, post-review only 4% (n=2) continued to 
have a measured leak >60 L/min.
Compliance
Data were available for 50 participants. Compliance improved 
following a change in the NIV prescription; there was a signif-
icant increase in the percentage of days during which NIV 
was used for more than 4 hours per night (the recommended 
minimal use20, pre-prescription change: 90% vs post-prescrip-
tion change: 96%, p=0.007) (figure 3). There was an increase 
in the total number of hours used each night; however, this 
was not statistically significant (pre-prescription change: 6.53 
vs post-prescription change: 6.94 hours, p=0.211) (figure 4). 
Using a definition of compliance of >4 hours use a day for 
70% of days, prior to NIV prescription review 58% of partici-
pants were compliant and after review this increased to 70% 
(p=0.180). Pre intervention, 19% (n=10) of participants used 
their NIV for <4 hours/night; in this subgroup, the mean use 
was 122 min/night, which increased to 270 min/night (mean 
difference 148 min; 95% CI 14 to 281, p=0.034) post interven-
tion for these people.
Hypercapnic ventilatory failure
PaCO2 data were available for only 21 participants (40%), 
as pre-review and post-review CBGs were only obtained if 
clinically indicated. There was a non-significant reduction 
in the incidence of ongoing hypercapnia (defined by a 
PaCO2 >6 kPa, pre-prescription change: 31% vs post-pre-
scription change: 11%, p=0.125) and measured PaCO2 
(mean difference 0.14; 95% CI −0.24 to 0.51, p=0.473). A 
multivariance analysis showed no significant difference in 
leak (p=0.75), compliance (p=0.65) or VT (p=0.65) between 
participants who had persistent hypercapnia and those 
who were eucapnic. Individual inspection of the six partici-
pants with persistent hypercapnia showed they were either 
non-compliant (n=4, with average daily NIV use of 129 min) 
or had ongoing interface issues (n=2).
Figure 2 Changes in tidal volume (VT, mL/kg/ideal body weight) following non-invasive ventilation prescription review.
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dIscussIon
These results demonstrate that the use of data down-
loaded via modems from domiciliary ventilators can 
lead to safe and clinically meaningful changes in domi-
ciliary NIV prescription and patient outcomes. The 
increase seen in VT is likely to be related to observed 
amendments in NIV prescriptions. The paired data 
show that there was a trend towards an increased IPAP 
and EPAP with a reduced rise time. There was also a 
change in the mean VT post-review of 8.8 mL/kg/ideal 
body weight compared with a pre-review of 10.0 mL/
kg/ideal body weight; this may have been due to an 
improvement in leak in some individuals resulting in 
the delivery of more accurate VT. Previous studies have 
reported VT as mL/kg rather than mL/kg/ideal body 
weight, making comparison difficult. A target VT of 
8–10 mL/kg/ideal body weight has been employed in 
other studies; therefore, the VT achieved in this study is 
comparable with other published studies.21
While not statistically significant, there was a reduc-
tion in the number of patients who had a leak greater 
than the manufacturer’s set threshold (reduction in 
Figure 3 Compliance with non-invasive ventilation percentage of days with >4 hours use.
Figure 4 Compliance with non-invasive ventilation average hours/day before and after non-invasive ventilation prescription 
review.
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66% of patients who had a leak greater than 60 L/
min) and an observed reduction in the measured 
leak; this may have been due to changes in the inter-
face prescription; however, the authors acknowledge 
that it is not possible to definitively attribute the leak 
reduction to this. In addition, since excessive leak 
may be identified by clinical features, such as dry 
mouth or excessive noise, the impact of the ventilator 
download data is difficult to judge in the absence of a 
control group. It is essential that leak is minimised to 
optimise ventilation; where leak is excessive (>60 L/
min) VT and efficiency of ventilation will be reduced.
15 
Additionally, excessive leak can impact on patient 
comfort which may reduce compliance.22 Further-
more, excessive leak can lead to overtightening of 
interface straps, which can cause pressure ulcers, a 
well-known side effect of NIV.22 The patient-centred 
benefits of reduced mask leak could include reduced 
side effects such as eye irritation, reduced sleep distur-
bance from leak noise and potential reduced impact 
on bed partners sleep comfort. Thus, although a 
statistically significant reduction in the leak value was 
not seen, there may have been patient-centred gains, 
although the authors acknowledge that we cannot 
specifically infer this from the data collected. Future 
work specifically investigating the patient-centred 
benefits in terms of patient comfort, side effects and 
sleep quality from ventilator download-led prescrip-
tion changes will help determine if the reduced leak 
has any clinical significance. Patient re-education on 
cleaning, caring and replacement of interfaces may 
have also contributed to the improvement in mask 
leak. Variation in algorithms used by different venti-
lator companies makes accurate comparison of inter-
face leak across studies difficult.
Hours of NIV use was similar to that of other studies18 
and was greater than the 4 hours often suggested by clini-
cians. Although not statistically significant, a change 
in actual hours of daily NIV use was seen, along with 
an increase in participants’ compliance, with a greater 
percentage of participants using NIV for more than 
4 hours/night (90% vs 96%). In those patients who were 
considered to have low compliance, defined by less than 
4 hours use of NIV on 70% of nights, there was an increase 
in the number of hours used on average by over 2 hours/
night following download of ventilator data to adjust NIV 
prescription to ensure adequate ventilation, minimis-
ation of leak and increase patient comfort. Suggesting 
that downloading ventilator data to assist in modifying 
NIV prescriptions is a useful adjunct to improve patient 
comfort and achieve a clinically meaningful increase 
in NIV compliance. Data from Masa et al23 and Borel et 
al24 suggest greater gains the longer NIV is used; thus a 
2-hour increase in NIV use could result in greater patient 
benefit. Furthermore, the small sample size and hetero-
geneity of the population in this study may have resulted 
in a statistical underestimation of the changes observed 
in NIV compliance.
Overall, there was a reduction in use of pillows and nasal 
masks and an increase in prescription of full face and diver 
masks. Which suggests some patients may have been expe-
riencing a significant leak (particularly from the mouth) or 
comfort issues which could have adversely affected compli-
ance. It is likely that there was no one reason for increase 
in compliance and the cause is probably specific to each 
patient. Collecting patient comfort scores in future studies 
would provide more insight into this important area.
Measurements for PaCO2 levels pre-review and post-re-
view were available for 21 participants. While not statis-
tically significant, there was an observed reduction in 
PaCO2 and an overall reduction in the percentage of 
patients with ongoing hypercapnia, with 57% of patients 
having a reduction of their PaCO2 to less than 6.5 kPa. 
We acknowledge that these data have been measured in 
a small number of patients and acknowledge that any 
conclusion on the effect of ventilator data downloads on 
PaCO2 requires robust, prospective data.
limitations, bias and confounding factors
As this was a pragmatic clinically based study, there are 
a number of areas to be considered about the findings. 
First, the study design did not include a control group 
and thus the effect of the intervention is uncertain. 
Second, it was not feasible to blind the investigators 
collecting data, which may have resulted in observer 
bias; however, the objective nature of the data helps 
mitigate this risk.25 To further minimise observer 
bias, investigators collecting data were not involved in 
participants’ reviews. Third, this was a relatively small 
sample size in a heterogeneous population. Greater 
changes may have been seen in subgroups according to 
underlying disease pathology. Due to the novel nature 
of utilising ventilator data downloads, a sample size 
could not be calculated due to the paucity of previous 
literature. Additionally, the reliability of the software 
(EncoreAnywhere, Philips Respironics) has not been 
tested in bench studies, and reliability has not been 
reported. Therefore, the potential for measurement 
error is acknowledged. In addition, this software is 
only able to provide trend data for the measurement 
reported. Finally, we acknowledge the potential for the 
Hawthorne effect to have occurred as we were moni-
toring measurements not previously monitored.
Unrelated to the study, 12 participants died before 
their review appointment. Although attrition due 
to death is arguably inevitable in a study including 
domiciliary patients with NIV, it may nonetheless have 
contributed to study bias.
It was not possible to obtain CBG results pre-review and 
post-review for all participants; PaCO2 data are therefore 
at risk of measurement bias and should be interpreted 
with caution. An independent and blinded statistician 
completed the data analysis, thus minimising reporting and 
observer bias. Multiple interventions were conducted at the 
review appointment, making it difficult to ascertain which 
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intervention had the biggest impact on compliance. Partici-
pants signed data protection consent forms for the applica-
tion of a modem. They were therefore all aware that their 
NIV usage was being monitored. For some patients knowing 
that they were being monitored could cause behaviour 
change, thus, increasing compliance.
This study was designed to assess the clinical implica-
tions of utilising ventilator data downloads. The authors 
acknowledge that the lack of cost-effectiveness data is a 
limitation, however, a different study design would have 
been required to assess cost-effectiveness. For this study, 
assessment of the ventilator data downloads outside of 
the clinical appointments was undertaken by a consultant 
physiotherapist, the EncoreAnywhere system (Philips 
Respironics) has a built in flagging system, allowing clini-
cians’ to prioritise patients with clinical concerns. Where 
a patient required a review of their ventilator data down-
load, this was estimated to take approximately 3 min per 
patient. This may be offset by a reduced need for face-
to-face clinical assessment. Future studies in this area 
should be designed to assess value in terms of cost as well 
as clinical effectiveness.
conclusIon
Results from this study have demonstrated employing 
ventilator download functions can inform clinicians’ 
decision-making to enable the optimal delivery of 
domiciliary NIV. Using ventilator data downloads 
in this outpatient setting facilitated an early, objec-
tive assessment of leak and ventilator prescriptions. 
Where outpatient NIV establishment and review are 
undertaken in lieu of traditional and more expensive 
inpatient environments, ventilator data downloads 
can provide clinicians with essential information, and 
therefore can be a useful interventional adjunct in 
the clinicians’ toolbox.
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